# The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients

Study · id `cardio:ct-nct01061060` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01061060](<https://clinicaltrials.gov/study/NCT01061060>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01061060

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT01061060. Randomized; quadruple masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT01061060, source copy `cardio:ctgov-nct01061060-2016-02-15`, retrieved 2026-10-26)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT01061060, source copy `cardio:ctgov-nct01061060-2016-02-15`, retrieved 2026-10-26)
- Primary completion: 2010-10 (actual) (ClinicalTrials.gov record NCT01061060, source copy `cardio:ctgov-nct01061060-2016-02-15`, retrieved 2026-10-26)
- Completion: 2010-10 (actual) (ClinicalTrials.gov record NCT01061060, source copy `cardio:ctgov-nct01061060-2016-02-15`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01061060, source copy `cardio:ctgov-nct01061060-2016-02-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01061060-2016-02-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients
- Condition: Type 2 Diabetes Mellitus
- Condition: Peripheral Microvascular Symptoms
- Intervention (Drug): Prostaglandin I2
- Intervention (Drug): Placebo
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER
- Collaborator: Astellas Pharma Korea, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)
- Registry lists this organization as a collaborator: Astellas Pharma Korea, Inc. (`cardio:org-astellas-pharma-korea-inc`)

## Provenance

Content hash: 650bdec53af29e60255dc51dac8cf86111bf5e54609cb34a903eeec4053227aa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
